Published in J Cancer Res Clin Oncol on January 01, 1997
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet (1990) 3.29
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Activation of natural killer cells via the p75 interleukin 2 receptor. J Exp Med (1989) 1.95
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol (1990) 1.74
An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology (1994) 1.49
Characterization of functional surface structures on human natural killer cells. Adv Immunol (1988) 1.30
Prothymosin alpha: a biologically active protein with random coil conformation. Biochemistry (1995) 1.22
Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction. J Exp Med (1989) 1.17
Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease. J Immunol (1982) 1.14
Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg (1986) 1.11
Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells. Immunology (1989) 0.97
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int J Cancer (1991) 0.92
Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett (1994) 0.90
Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg (1983) 0.88
Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer (1994) 0.84
Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res (1992) 0.84
Enhanced therapeutic effects of anti-tumour agents against growth and metastasis of colon carcinoma 26 when given in combination with interferon and interleukin-2. Clin Exp Metastasis (1994) 0.81
Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro. J Biol Response Mod (1990) 0.80
Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients. Surgery (1984) 0.80
High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: results of a randomized multicenter clinical trial. Anticancer Res (1994) 0.80
Evidence that induction and regulation of lymphokine-activated killer (LAK) activity are mediated by changes in tumour-binding potential of lymphocytes after activation by interleukin-2 (IL-2). Immunology (1991) 0.79
Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets. Int J Cancer (1991) 0.79
Thymosin alpha 1 effects, in vitro, on lymphokine-activated killer cells from patients with primary immunodeficiencies: preliminary results. Int J Immunopharmacol (1994) 0.79
Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients. Cancer Immunol Immunother (1986) 0.78
Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha. Cancer Immunol Immunother (1992) 0.77
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother Emphasis Tumor Immunol (1994) 0.77
Evaluation of the MTT and SRB assays for testing LAK cell-mediated growth inhibition of various adherent and non-adherent tumor target cells. J Immunol Methods (1994) 0.76
Prothymosin alpha restores depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer. Int J Cancer (1993) 0.76
Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity. Lymphokine Cytokine Res (1992) 0.76
Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). Br J Cancer (1991) 0.75
Prothymosin alpha receptors on peripheral blood mononuclear cells. FEBS Lett (1994) 0.75
Phytohemagglutin-stimulated human T cell: prothymosin alpha as an accessory signal. J Biol Regul Homeost Agents (1990) 0.75
Prothymosin alpha augments deficient antitumor activity of monocytes from melanoma patients in vitro. Anticancer Res (1995) 0.75
Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines. Immunol Ser (1989) 0.75
Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Cancer Res (1988) 0.75
Prothymosin alpha 1 modulates lymphokine-activated killer cell activity and IL-2 production by peripheral blood lymphocytes from melanoma patients in vitro. Int J Immunopharmacol (1995) 0.75
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol (2003) 2.16
Some properties of a nuclear binding site of estradiol. J Mol Biol (1967) 1.79
Useful buffer and gel systems for polyacrylamide gel electrophoresis. Z Klin Chem Klin Biochem (1972) 1.44
[Combination of interferon-alpha with cytostatic drugs: a potentially successful therapeutic approach in metastatic melanoma]. Hautarzt (1992) 1.38
Prothymosin alpha: a biologically active protein with random coil conformation. Biochemistry (1995) 1.22
Potential pitfalls of [3H]thymidine techniques to measure cell proliferation. Cell Tissue Kinet (1981) 1.21
Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Pancreas (1996) 1.11
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer (2004) 1.04
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol (1998) 1.00
Turnover of template-bound histone. Proc Natl Acad Sci U S A (1965) 0.98
[The biochemical action of steroid hormones]. Med Monatsschr (1967) 0.97
Primary malignant melanoma of the esophagus. Virchows Arch A Pathol Anat Histol (1979) 0.93
Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J Mol Med (Berl) (1996) 0.93
Integrin alpha6beta1 role in metastatic behavior of human pancreatic carcinoma cells. Int J Cancer (1999) 0.93
Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie (2002) 0.91
Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Recent Results Cancer Res (1996) 0.90
Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett (1994) 0.90
In vitro culture of lymphocyte colonies in agar capillary tubes after PHA-stimulation. J Immunol Methods (1977) 0.90
Isolation and characterization of two forms of an acidic bromelain stem proteinase. J Protein Chem (1998) 0.89
Phosphorylation of p125FAK and paxillin focal adhesion proteins in src-transformed cells with different metastatic capacity. FEBS Lett (1999) 0.89
The formation of B-lymphocyte colonies in agar contained in glass capillaries. Immunology (1978) 0.88
Integrin alpha5beta1: a potent inhibitor of experimental lung metastasis. Clin Exp Metastasis (1998) 0.88
Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int J Cancer (2000) 0.88
Compliance of physicians and patients with a consensus protocol for treatment of advanced breast cancer. J Cancer Res Clin Oncol (1989) 0.88
Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. Int J Oncol (1998) 0.86
Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. Oncol Rep (1999) 0.86
Bromelain reversibly inhibits invasive properties of glioma cells. Neoplasia (2002) 0.85
Successful emergency splenectomy during pregnancy in a patient with life-threatening idiopathic thrombocytopenia. Case report. J Perinat Med (1996) 0.84
Docetaxel enhances the expression of E-cadherin and carcinoembryonic antigen (CEA) on human colon cancer cell lines in vitro. Anticancer Res (1997) 0.84
Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Int J Oncol (1998) 0.83
De novo expression of the alpha5beta1-fibronectin receptor in HT29 colon-cancer cells reduces activity of C-SRC. Increase of C-SRC activity by attachment on fibronectin. Int J Cancer (1998) 0.83
Drug evaluation on haemopoietic cells in vitro. I. A micro agar colony assay with semi-automatic optical monitoring. Arzneimittelforschung (1978) 0.82
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. Onkologie (2001) 0.82
Isolation and partial characterization of basic proteinases from stem bromelain. J Protein Chem (1995) 0.82
Effects of differentiation inducers on cell phenotypes of cultured nontransformed and immortalized mammary epithelial cells: a comparative immunocytochemical analysis. Tumour Biol (2000) 0.81
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia (1996) 0.81
Adjuvant treatment of colon and rectal cancer: impact of chemotherapy, radiotherapy, and immunotherapy on routine postsurgical patient management. Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Recent Results Cancer Res (1996) 0.81
Cytostatic effects of various alkyl phospholipid analogues on different cells in vitro. Anticancer Res (1993) 0.80
A rapid and sensitive fluorometric screening assay using YO-PRO-1 to quantify tumour cell invasion through Matrigel. Clin Exp Metastasis (1996) 0.80
A lymphocyte chalone assay using lymphocyte colony growth in agar capillaries. Virchows Arch B Cell Pathol (1977) 0.80
Automated scanning of bone marrow cell colonies growing in agar-containing glass capillaries. Exp Cell Res (1976) 0.80
IL-4 and TNF-alpha induce changes in integrin expression and adhesive properties and decrease the lung-colonizing potential of HT-29 colon carcinoma cells. Clin Exp Metastasis (1996) 0.80
Colony growth of mouse bone marrow cells in agar contained in glass capillaries. Blut (1976) 0.80
Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood (1996) 0.80
Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. Cancer Res (1992) 0.80
[Malignant pleural effusions. Pathophysiology, diagnosis and therapy]. Dtsch Med Wochenschr (1985) 0.80
Growth kinetics of L1210 leukemic cells exposed to different concentration courses of methotrexate in vitro. Cancer Chemother Pharmacol (1994) 0.79
Inhibition of cells in culture by polyamines does not depend on the presence of ruminant serum. Cell Tissue Kinet (1983) 0.79
Inhibition of agar colony formation by partially purified granulocyte extracts (chalone). Virchows Arch B Cell Pathol (1977) 0.79
Reduced binding of carcinogenic hydrocarbons to DNA of mouse skin during inhibition of DNA synthesis. Nature (1968) 0.79
Thymosin alpha 1 effects, in vitro, on lymphokine-activated killer cells from patients with primary immunodeficiencies: preliminary results. Int J Immunopharmacol (1994) 0.79
The effect of selected antiarrhythmic drugs on neutrophil free oxygen radicals production measured by chemiluminescence. Basic Res Cardiol (1992) 0.78
Stimulation of clonal tumor cell growth in vitro by inhibiting the serum polyamine oxidase activity. J Cancer Res Clin Oncol (1983) 0.78
Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo. In Vivo (1999) 0.78
Chronic gonadal toxicity in patients with testicular cancer after chemotherapy. Eur J Cancer Clin Oncol (1986) 0.78
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann Oncol (1997) 0.78
Screening for specific calf thymus inhibitors (chalones) of T-lymphocyte proliferation. Hoppe Seylers Z Physiol Chem (1979) 0.78
Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions. Curr Top Microbiol Immunol (1996) 0.78
Prothymosin alpha1 antagonizes the inhibitory effects of transforming growth factor-beta1 on the adhesion of peripheral blood lymphocytes to human umbilical vein endothelial cells. Int J Mol Med (1998) 0.78
Novel approaches to immunotherapy using thymic peptides. Immunol Today (1997) 0.77
Estradiol-mediated template activity of mouse and rat uterine chromatin: an unsolved problem. Biochim Biophys Acta (1971) 0.77
Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA. Pharm Res (1999) 0.77
Prothymosin alpha1 effects on IL-2-induced expression of LFA-1 on lymphocytes and their adhesion to human umbilical vein endothelial cells. J Interferon Cytokine Res (1997) 0.77
Current treatment modalities in advanced colorectal carcinoma. Recent Results Cancer Res (1996) 0.77
Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. Oncology (2000) 0.77
Tumor stem cell cloning in agar-containing capillaries. Naturwissenschaften (1981) 0.76
Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma (1994) 0.76
Preclinical studies with prothymosin alpha1 on mononuclear cells from tumor patients. Int J Immunopharmacol (1998) 0.76
Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer. Pharm World Sci (1999) 0.76
Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol (1987) 0.76
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma. Eur J Cancer (1996) 0.76
Prothymosin alpha 1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients. Int J Immunopharmacol (1997) 0.76
Evidence for a rat granulocyte chalone effect on the proliferation of normal human bone marrow and of myeloid leukemias. Acta Haematol (1979) 0.76
Bromelain induces the differentiation of leukemic cells in vitro: an explanation for its cytostatic effects? Planta Med (1988) 0.76
Cisplatin stimulates the expression from the human immunodeficiency virus long terminal repeat sequences in human fibroblasts. Anticancer Drugs (1990) 0.76
Effect of interleukin-3 and granulocyte-macrophage colony-stimulating factor on growth of xenotransplanted human tumour cell lines in nude mice. Eur J Cancer (1992) 0.76
Synergistic interactions between interferon beta and carboplatin on SK-MEL 28 human melanoma cell growth inhibition in vitro. J Cancer Res Clin Oncol (1995) 0.76
Polyacrylamide gel electrophoresis on micro slabs. Anal Biochem (1972) 0.76
Evaluation of the MTT and SRB assays for testing LAK cell-mediated growth inhibition of various adherent and non-adherent tumor target cells. J Immunol Methods (1994) 0.76
Prothymosin alpha 1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients. Int J Immunopharmacol (1997) 0.75
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol (1993) 0.75
T-lymphocyte colony formation of murine thymocytes in agar contained in glass capillaries. Blut (1987) 0.75
Glutathione: an in vitro granulopoiesis inhibitor at nanomolar concentration, isolated from calf spleen. Exp Hematol (1990) 0.75
A colorimetric immunoassay for the detection of E-cadherin and carcinoembryonic antigen (CEA) expression on human colon carcinoma cell lines in vitro. Cancer Lett (1996) 0.75
The thymus extract Thymex-L potentiates the retinoic acid-induced differentiation of the human myeloid leukemia cell line HL-60. Biochim Biophys Acta (1995) 0.75
Induction of the c-myc but not the cH-ras promoter by platinum compounds. Biochem Pharmacol (1995) 0.75
Prothymosin alpha 1 modulates lymphokine-activated killer cell activity and IL-2 production by peripheral blood lymphocytes from melanoma patients in vitro. Int J Immunopharmacol (1995) 0.75
Combined effects of differentiation-inducing factor and other cytokines on induction of differentiation of mouse myeloid leukemic cells. Jpn J Cancer Res (1989) 0.75
Polyacrylamide gel electrophoresis in clinical chemistry: problems of standardization and performance. Clin Chim Acta (1972) 0.75
Defined, serum-free culture conditions for the GM-micro-clonogenic assay using agar-capillaries. Blut (1989) 0.75